US, European Covid vaccine developers make pledge to uphold testing rigour | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
June 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JUNE 12, 2025
US, European Covid vaccine developers make pledge to uphold testing rigour

Coronavirus chronicle

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm

Related News

  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis
  • US cities brace for more protests as parts of Los Angeles placed under curfew
  • Stocks offer muted cheer to latest US-China trade detente

US, European Covid vaccine developers make pledge to uphold testing rigour

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines"

Reuters
08 September, 2020, 04:35 pm
Last modified: 08 September, 2020, 04:40 pm
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labeled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

Nine leading US and European vaccine developers pledged on Tuesday to uphold the scientific standards that their experimental immunisations will be held against, amid a hurried global race to contain the pandemic.

The companies, including Pfizer, GlaxoSmithKline and AstraZeneca, in a joint statement made a "historic pledge... to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first Covid-19 vaccines".

The unusual move to promise to play by well-established rules underlines a highly politicised debate over what action is needed to quickly rein in the spread of the deadly disease and to jumpstart global business and trade.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

The head of the US Food and Drug Administration (FDA) said last month that the normal approval process may be bypassed for a Covid-19 vaccine as long as officials were convinced the benefits outweigh the risks, prompting a call for caution from the World Health Organisation.

Developers globally have yet to produce large-scale trial data showing actual infections in participants, yet Russia granted approval to a Covid-19 vaccine last month, prompting some Western experts to criticize a lack of testing.

The head of China's Sinovac Biotech said most of its employees and their families have already taken an experimental vaccine developed by the Chinese firm under the country's emergency-use programme.

"We want it to be known that also in the current situation we are not willing to compromise safety and efficacy," said co-signatory Ugur Sahin, the chief executive of Pfizer's German partner BioNTech.

"Apart from the pressure and the hope for a vaccine to be available as fast as possible, there is also a lot of uncertainty among people that some development steps may be omitted here," he added.

BioNTech and Pfizer have raised the prospect of unveiling pivotal trial data in October, potentially placing it at the centre of bitter US presidential politics ahead of the Nov. 3 election.

According to the statement, the nine companies pledge to follow established guidance from expert regulatory authorities such as the FDA.

Among other hurdles, approval must be based on large, diverse clinical trials with comparative groups that do not receive the vaccine in question. Participants and those working on the trial must not know which group they belong to, according to the pledge.

BioNTech's Sahin added there must be statistical certainty of 95 percent, in some cases higher, that a positive reading on efficacy does not just come from random variations but reflects the underlying workings of the compound.

The list of co-signatories is completed by Johnson & Johnson , Merck & Co, Moderna, Novavax and Sanofi.

Sahin said inclusion in the pledge broadly reflected a significant vaccines market share or a leading position in coronavirus vaccine development.

The frenetic development race has intensified safety concerns about an inoculation, polls have shown.

Western regulators have stressed they would not cut corners but rather prioritise the review workload and allow for development steps in parallel that would normally be handled consecutively.

covid-19 vaccine / US / Europe / Pfizer / AstraZeneca Covid-19 Vaccine / GlaxoSmithKline

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India plane crash: Not all dead, one survivor identified, 204 bodies recovered
  • CA Yunus meets King Charles
    CA Yunus meets King Charles
  • News of The Day, 12 JUNE 2025
    News of The Day, 12 JUNE 2025

MOST VIEWED

  • File photo of ex-prime minister Sheikh Hasina and her son Sajeeb Wazed Joy. Photo: Collected
    Joy spends Eid with Hasina in India: Indian media
  • Infofgraphics: TBS
    DGHS issues 11-point directive to prevent spread of Covid-19 in Bangladesh
  • Saifuzzaman Chowdhury. Photo: Collected
    UK crime agency now freezes assets of ex-land minister Saifuzzaman: AJ
  • File photo of BNP Standing Committee Member Amir Khasru Mahmud Chowdhury. Photo: Collected
    Khasru flies to London ahead of Yunus-Tarique meeting
  • Chief Adviser Muhammad Yunus speaks at the Chatham House in London on 11 June 2025. Photo: CA Press Wing
    No desire to be part of next elected govt: CA Yunus
  • Illustration: Khandaker Abidur Rahman/TBS
    Three hospitals ‘held hostage’ as discharged July uprising injured keep occupying beds

Related News

  • Marines prepare for Los Angeles deployment as protests spread across US
  • Deal to get US-China trade truce back on track is done, Trump says
  • China's mega-embassy faces its MAGA nemesis
  • US cities brace for more protests as parts of Los Angeles placed under curfew
  • Stocks offer muted cheer to latest US-China trade detente

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

1d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

1d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

3d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

5d | Bangladesh

More Videos from TBS

What exactly happened to the ill-fated Boeing aircraft?

What exactly happened to the ill-fated Boeing aircraft?

1h | TBS World
Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28

Govt to set up Debt Office as loan burden to hit Tk29 lakh cr by FY28

1h | TBS Insight
Curfew imposed for second night in Los Angeles

Curfew imposed for second night in Los Angeles

2h | TBS World
When will coronavirus testing start in hospitals?

When will coronavirus testing start in hospitals?

2h | TBS Today
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net